Authors:
Remick, SC
Sedransk, N
Haase, RF
Blanchard, CG
Ramnes, CR
Nazeer, T
Mastrianni, DM
Dezube, BJ
Citation: Sc. Remick et al., Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: Evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up, AM J HEMAT, 66(3), 2001, pp. 178-188
Authors:
Kempf, W
Margolin, DH
Dezube, BJ
Kadin, ME
Letvin, NL
Koralnik, IJ
Citation: W. Kempf et al., Clinicopathological characterization of an HIV-2-infected individual with two clonally unrelated primary lymphomas, AM J HEMAT, 65(4), 2000, pp. 302-306
Authors:
Moore, JD
Dezube, BJ
Gill, P
Zhou, XJ
Acosta, EP
Sommadossi, JP
Citation: Jd. Moore et al., Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma, CANC CHEMOT, 46(3), 2000, pp. 173-179
Citation: Bj. Dezube, The role of human immunodeficiency virus-I in the pathogenesis of acquiredimmunodeficiency syndrome-related Kaposi's sarcoma: The importance of an inflammatory and angiogenic milieu, SEMIN ONCOL, 27(4), 2000, pp. 420-423
Authors:
Dezube, BJ
Dahl, TA
Wong, TK
Chapman, B
Ono, M
Yamaguchi, N
Gillies, SD
Chen, LB
Crumpacker, CS
Citation: Bj. Dezube et al., A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: A phase I study, J INFEC DIS, 182(2), 2000, pp. 607-610
Citation: Lf. Brown et al., Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma, AM J PATH, 156(6), 2000, pp. 2179-2183
Authors:
Skobe, M
Brown, LF
Tognazzi, K
Ganju, RK
Dezube, BJ
Alitalo, K
Detmar, M
Citation: M. Skobe et al., Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma, J INVES DER, 113(6), 1999, pp. 1047-1053
Authors:
Aziz, N
Nishanian, P
Taylor, JMG
Mitsuyasu, RT
Jacobson, JM
Dezube, BJ
Lederman, MM
Detels, R
Fahey, JL
Citation: N. Aziz et al., Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection, J INFEC DIS, 179(4), 1999, pp. 843-848